Continuous glucose monitoring reduces both hypoglycaemia and HbA1c in hypoglycaemia-prone type 1 diabetic patients treated with a portable pump.

Division of Diabetes, Nutrition and Metabolic Disorders, CHU de Liège, University of Liège, CHU Sart Tilman, bâtiment B35, 4000 Liège, Belgium.
Diabetes & Metabolism (Impact Factor: 2.85). 11/2010; 36(5):409-13. DOI: 10.1016/j.diabet.2010.08.001
Source: PubMed

ABSTRACT This study aimed to assess the effectiveness of continuous glucose monitoring (CGM) for glucose control in type 1 diabetic patients treated by continuous subcutaneous insulin infusion (CSII) and presenting with frequent hypoglycaemic episodes.
Thirteen patients with type 1 diabetes (diabetes duration: 25±15 years; CSII duration: 5.5±7.0 years), with more than six recorded capillary blood glucose (CBG) values <60 mg/dL, according to their metres for the past 14 days, were offered the permanent use of a CGM device (Guardian RT(®), Medtronic) plus ongoing self-monitoring of blood glucose (SMBG) for 12 weeks, followed by a 12-week crossover period of SMBG only, or vice versa. Glucose control, determined by recorded 14-day CBG values <60 mg/dL and HbA(1c) levels, and quality of life according to the Diabetes Quality of Life (DQOL) questionnaire, were assessed at baseline, and after 12- and 24-week follow-ups.
Four patients withdrew from the study during the first period (of whom three were using CGM). In the nine study completers, the number of low CBG values decreased significantly from 13.9±9.2 to 7.6±6.8 (P=0.011) when patients used CGM, in either the initial or final trial period, while a decrease in HbA(1c) from 8.3±0.7 to 7.7±0.6% (P=0.049) was also observed, in contrast to the absence of any significant differences during the SMBG-only period. DQOL scores were also essentially unaffected.
This pilot observational study supports the hypothesis that CGM use can significantly improve overall glucose control while reducing hypoglycaemic episodes in hypoglycaemia-prone type 1 diabetic patients treated by CSII.


Available from: Eric Renard, Jun 03, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Insulin delivery in a closed-loop mode has been a dream for many patients with insulin-treated diabetes since bedside artificial pancreas (AP) systems were developed in the 1970s. Beside safe near-normal glucose levels, the goal of AP is to alleviate patients' burden and fear of continual adjustment of insulin delivery needed to cope with daily activities and events. Portable pumps using subcutaneous (SC) insulin infusion and 'needle-type' enzymatic sensors allowing continuous glucose monitoring (CGM) in the interstitial SC fluid are typically used in the current AP prototypes. Model predictive control algorithms which take into account the delays inherent with SC insulin infusion and glucose sensing have shown improved glucose control in hospital setting. Currently, pilot trials are performed in home-like conditions to assess the technical feasibility, safety and efficacy of glucose control, and patients' ability to manage AP. Recently developed wearable smart phone-based platforms connect wirelessly to the insulin pump and the CGM, run control algorithms, provide online information to/from the patient, and allow remote monitoring reaching a new frontier - first outpatient experiments. The future holds expansion of home trials supporting the approval of systems which could revolutionize diabetes treatment and make easier the daily life of patients with diabetes.
    Diabetes research and clinical practice 09/2013; DOI:10.1016/j.diabres.2013.09.009 · 2.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background/Objectives:Glycogen storage disease type I (GSD I) is an autosomal recessive metabolic disorder caused by defects in the glucose-6-phosphatase complex. Deficient activity in the glucose-6-phosphatase-α catalytic unit characterizes GSD Ia and defects in the glucose-6-phosphate transporter protein characterize GSD Ib. Type Ia involves the liver, kidney and intestine (and Ib also leukocytes), and the clinical manifestations are hepatomegaly, failure to thrive, severe fasting hypoglycemia within 3-4 h after a meal, hyperlactatemia, hyperuricemia and hyperlipidemia. The aim of the present study was to examine the safety and efficacy of a continuous subcutaneous glucose monitoring system to determine the magnitude and significance of hypoglycemia in GSD I and to evaluate the efficacy of the revised dietary treatment.Subjects/Methods:Sixteen children with GSD I were studied over a 72-h period. Continuous glucose monitoring (CGM) was repeated in all patients 3-6 months after the first monitoring to examine the effects of revised dietary instructions on glycemic control.Results:All the patients completed the study without any major adverse events. Significant periods of asymptomatic hypoglycemia (below 4 mmol/l, 70 mg/dl) were noted. There was a close correlation between CGM sensor and capillary blood glucose values measured by a glucometer. CGM indicated a considerable reduction in duration of hypoglycemia, liver size and improvements in secondary metabolic derangements such as hyperlacticacidemia and hyperlipidemia.Conclusions:CGM could be applied in the clinical setting to help the physician to identify hypoglycemic events, and repeated CGM may serve as a safe and useful tool for the assessment of the long-term management of patients with GSD I.European Journal of Clinical Nutrition advance online publication, 23 October 2013; doi:10.1038/ejcn.2013.186.
    European journal of clinical nutrition 10/2013; 68(1). DOI:10.1038/ejcn.2013.186 · 2.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The ambulatory glucose profile is an instrument used to detect blood glucose patterns from patient results by recording blood glucose results or, more usually, by continuous glucose monitoring. This instrument analyzes the changes in glucose levels obtained over a number of days, and expresses the data, depending on the time of the day, using the median and the 10th, 25th, 75th and 90th percentiles. It is very useful for identifying glycemic patterns over the day, to quantify blood glucose variability, and to classify hypoglycemia risk according to time. This should be complemented with the analysis of individual blood glucose data, diet, and exercise, to detect potential causes of variability and correct them.
    07/2014; DOI:10.1016/j.avdiab.2014.06.002